ATE189394T1 - Methode zur behandlung von viralen infektionen - Google Patents

Methode zur behandlung von viralen infektionen

Info

Publication number
ATE189394T1
ATE189394T1 AT92925395T AT92925395T ATE189394T1 AT E189394 T1 ATE189394 T1 AT E189394T1 AT 92925395 T AT92925395 T AT 92925395T AT 92925395 T AT92925395 T AT 92925395T AT E189394 T1 ATE189394 T1 AT E189394T1
Authority
AT
Austria
Prior art keywords
crp
modified
virus
viral infections
treating viral
Prior art date
Application number
AT92925395T
Other languages
English (en)
Inventor
Lawrence A Potempa
Original Assignee
Immtech Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immtech Int Inc filed Critical Immtech Int Inc
Application granted granted Critical
Publication of ATE189394T1 publication Critical patent/ATE189394T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT92925395T 1991-11-27 1992-11-23 Methode zur behandlung von viralen infektionen ATE189394T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79944891A 1991-11-27 1991-11-27
PCT/US1992/010126 WO1993010799A1 (en) 1991-11-27 1992-11-23 Method of treating viral infections

Publications (1)

Publication Number Publication Date
ATE189394T1 true ATE189394T1 (de) 2000-02-15

Family

ID=25175937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92925395T ATE189394T1 (de) 1991-11-27 1992-11-23 Methode zur behandlung von viralen infektionen

Country Status (8)

Country Link
US (1) US5585349A (de)
EP (1) EP0616535B1 (de)
JP (1) JP3457309B2 (de)
AT (1) ATE189394T1 (de)
AU (1) AU662787B2 (de)
CA (1) CA2123786C (de)
DE (1) DE69230643T2 (de)
WO (1) WO1993010799A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239099B1 (en) 1991-11-27 2001-05-29 Immtech International, Inc. Methods of treating viral infections
US5874238A (en) * 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
DE69716741T2 (de) * 1996-01-25 2003-06-12 Profylakse Aps, Odense Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten
US5850333A (en) * 1997-03-19 1998-12-15 Ingersoll-Rand Company Enclosure for machine control panel
US6331403B1 (en) 1998-08-19 2001-12-18 Lawrence A. Potempa Use of mCRP to slow cell growth and to promote maturation of cells
US6190670B1 (en) * 1999-04-12 2001-02-20 Immtech International Inc. Use of mCRP to enhance immune responses
WO2005058359A2 (en) * 2003-12-15 2005-06-30 Theralogic Gmbh & Co. Kg Method for neutralizing effects of crp for increasing immune reactions to hiv
SG10201503351RA (en) 2010-01-19 2015-06-29 Harvard College Engineered Opsonin for Pathogen Detection and Treatment
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
EP3331549B1 (de) 2015-08-06 2020-12-23 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68925899T2 (de) * 1988-04-04 1996-10-02 Byron E Anderson Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen
DD294568A5 (de) * 1989-07-14 1991-10-02 Humboldt-Universitaet,Direkt. F. Forsch.,De Verfahren zur bestimmung von c-reaktivem protein
NL9100434A (nl) * 1991-03-11 1992-10-01 Rijksuniversiteit Farmaceutische preparaten voor de bestrijding van virale infecties en immuundeficientieziekten, de bereiding en toepassing daarvan.
WO1992020715A1 (en) * 1991-05-16 1992-11-26 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US5283238A (en) * 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein

Also Published As

Publication number Publication date
AU3146893A (en) 1993-06-28
AU662787B2 (en) 1995-09-14
EP0616535A1 (de) 1994-09-28
EP0616535B1 (de) 2000-02-02
CA2123786C (en) 2000-08-01
WO1993010799A1 (en) 1993-06-10
DE69230643T2 (de) 2000-06-21
CA2123786A1 (en) 1993-06-10
EP0616535A4 (de) 1995-07-12
DE69230643D1 (de) 2000-03-09
US5585349A (en) 1996-12-17
JP3457309B2 (ja) 2003-10-14
JPH07501544A (ja) 1995-02-16

Similar Documents

Publication Publication Date Title
DE69230643D1 (de) Methode zur behandlung von viralen infektionen
Gellis et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat
NO874364D0 (no) Antivirus-immunoterapeutisk middel og fremstilling derav.
ATE73663T1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
DK0431129T3 (da) Fremgangsmåder til inaktivering af virus i viruskontaminerede farmaceutiske præparater
DE3850542D1 (de) Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
DE69718612D1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
EP0199479A3 (en) Ozone decontamination of blood and blood products
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
EA199700215A1 (ru) Защита от вирусных инфекций путем колонизации слизистых оболочек генетически модифицированными бактериями
ATE362379T1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
DE68906735D1 (de) Pharmazeutische zubereitung zur behandlung von viruskrankheiten mit leber-extrakt.
ATE136468T1 (de) Impfstoff zur behandlung von hsv
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
ATE88752T1 (de) Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole.
ATE155795T1 (de) Verwendung von leukoregulin zur behandlung von mit einem envelope-virus infizierten tier
RU94038588A (ru) Способ лечения вторичного иммунодефицита (вид)
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
MC2306A1 (fr) Peptides bloquant les infections par le virus de l'immunodeficience humaine et methode de leur utilisation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties